Usefulness of urinary kidney injury molecule-1 (Kim-1) as a biomarker for cisplatin-induced sub-chronic kidney injury

被引:17
作者
Nan-ya, Ken-ichiro [1 ,2 ]
Kajihara, Masatomo [3 ]
Kojima, Natsuki [4 ]
Degawa, Masakuni [2 ]
机构
[1] Kyowa Hakko Kirin Co Ltd, Drug Discovery Res Labs, Nagaizumi, Shizuoka 4118731, Japan
[2] Univ Shizuoka, Sch Pharmaceut Sci, Dept Mol Toxicol, Suruga Ku, Shizuoka 4228526, Japan
[3] Kyowa Hakko Kirin Co Ltd, Dev Res Labs, Nagaizumi, Shizuoka 4118731, Japan
[4] Kyowa Hakko Kirin Co Ltd, Discovery & Dev Res Promot Labs, Nagaizumi, Shizuoka 4118731, Japan
关键词
Kim-1; urinary biomarkers; sub-chronic kidney injury; cisplatin; rat; 2; STRAINS; NEPHROTOXICITY; CLUSTERIN; EXPRESSION; MODEL; GENE; QUALIFICATION; NEED;
D O I
10.1002/jat.2999
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
We explored biomarkers suitable for monitoring sub-chronic kidney injury using the three rat models of cisplatin (CDDP)-induced kidney injury, which were designed to extend the current knowledge beyond the sub-acute exposure period. In the pilot study, a single intravenous administration of 1.5 mg kg(-1) CDDP to rats was confirmed to result in no histopathological changes. Subsequently, CDDP was intravenously administered to rats at a dose of 1.5 mg kg(-1) for 4 days at 24-h intervals (Experimental model 1) and for up to 10 weeks at weekly intervals (Experimental models 2 and 3), and the changes in blood and urine components, such as recently recommended urinary biomarkers (Kim-1, clusterin and so on) and traditional blood biomarkers (blood urea nitrogen and serum creatinine), were examined together with the histopathological changes in renal tissues during the development of the kidney injury in each model. In these experimental models, a significant increase in urinary Kim-1 was observed prior to the histopathological changes in renal tissues, and these changes were retained after the adverse histopathological changes. Significant changes in all of the other urinary biomarkers examined occurred along with the histopathological changes. In addition, the increase in urinary Kim-1 after weekly treatment with CDDP for 4 weeks was reduced in a time-dependent manner after cessation of the drug. The present findings indicate that urinary Kim-1 is the most useful biomarker for CDDP-induced rat sub-chronic kidney injury among the biomarkers examined. Copyright (c) 2014 John Wiley & Sons, Ltd. We explored biomarkers suitable for monitoring sub-chronic kidney injury using rat models of kidney injury induced by cisplatin (CDDP). CDDP was intravenously administered to rats at 1.5 mg kg(-1) for 4 days at 24-h intervals and for up to 10 weeks at weekly intervals, and the changes in blood and urine components were examined together with the histopathological changes in renal tissues. The present findings indicate that urinary kidney injury molecule-1 (Kim-1) is the most useful biomarker for CDDP-induced rat sub-chronic kidney injury.
引用
收藏
页码:124 / 132
页数:9
相关论文
共 45 条
  • [1] Cisplatin nephrotoxicity
    Arany, I
    Safirstein, RL
    [J]. SEMINARS IN NEPHROLOGY, 2003, 23 (05) : 460 - 464
  • [2] Next-generation biomarkers for detecting kidney toxicity
    Bonventre, Joseph V.
    Vaidya, Vishal S.
    Schmouder, Robert
    Feig, Peter
    Dieterle, Frank
    [J]. NATURE BIOTECHNOLOGY, 2010, 28 (05) : 436 - 440
  • [3] Chevalier RL, 1996, J AM SOC NEPHROL, V7, P1098
  • [4] Correa-Rotter R, 1998, J AM SOC NEPHROL, V9, P33
  • [5] Quantitative gene expression analysis in a nonhuman primate model of antibiotic-induced nephrotoxicity
    Davis, JW
    Goodsaid, FM
    Bral, CM
    Obert, LA
    Mandakas, G
    Garner, CE
    Collins, ND
    Smith, RJ
    Rosenblum, IY
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2004, 200 (01) : 16 - 26
  • [6] Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury
    Dieterle, Frank
    Perentes, Elias
    Cordier, Andre
    Roth, Daniel R.
    Verdes, Pablo
    Grenet, Olivier
    Pantano, Serafino
    Moulin, Pierre
    Wahl, Daniel
    Mahl, Andreas
    End, Peter
    Staedtler, Frank
    Legay, Francois
    Carl, Kevin
    Laurie, David
    Chibout, Salah-Dine
    Vonderscher, Jacky
    Maurer, Gerard
    [J]. NATURE BIOTECHNOLOGY, 2010, 28 (05) : 463 - U114
  • [7] Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
    Dieterle, Frank
    Sistare, Frank
    Goodsaid, Federico
    Papaluca, Marisa
    Ozer, Josef S.
    Webb, Craig P.
    Baer, William
    Senagore, Anthony
    Schipper, Matthew J.
    Vonderscher, Jacky
    Sultana, Stefan
    Gerhold, David L.
    Phillips, Jonathan A.
    Maurer, Gerard
    Carl, Kevin
    Laurie, David
    Harpur, Ernie
    Sonee, Manisha
    Ennulat, Daniela
    Holder, Dan
    Andrews-Cleavenger, Dina
    Gu, Yi-Zhong
    Thompson, Karol L.
    Goering, Peter L.
    Vidal, Jean-Marc
    Abadie, Eric
    Maciulaitis, Romaldas
    Jacobson-Kram, David
    Defelice, Albert F.
    Hausner, Elizabeth A.
    Blank, Melanie
    Thompson, Aliza
    Harlow, Patricia
    Throckmorton, Douglas
    Xiao, Shen
    Xu, Nancy
    Taylor, William
    Vamvakas, Spiros
    Flamion, Bruno
    Lima, Beatriz Silva
    Kasper, Peter
    Pasanen, Markku
    Prasad, Krishna
    Troth, Sean
    Bounous, Denise
    Robinson-Gravatt, Denise
    Betton, Graham
    Davis, Myrtle A.
    Akunda, Jackie
    McDuffie, James Eric
    [J]. NATURE BIOTECHNOLOGY, 2010, 28 (05) : 455 - 462
  • [8] Emeigh Hart Susan G, 2005, J Pharmacol Toxicol Methods, V52, P30, DOI 10.1016/j.vascn.2005.04.006
  • [9] Fenoglio C, 2005, ANTICANCER RES, V25, P4123
  • [10] Evaluation of Novel Acute Urinary Rat Kidney Toxicity Biomarker for Subacute Toxicity Studies in Preclinical Trials
    Fuchs, Tobias Christian
    Frick, Katharina
    Emde, Barbara
    Czasch, Stephanie
    von Landenberg, Friedrich
    Hewitt, Philip
    [J]. TOXICOLOGIC PATHOLOGY, 2012, 40 (07) : 1031 - 1048